Thrombotic Microangiopathies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major thrombotic microangiopathies markets are expected to exhibit a CAGR of 3.76% during 2024-2034.
The thrombotic microangiopathies market has been comprehensively analyzed in IMARC's new report titled "Thrombotic Microangiopathies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Thrombotic microangiopathies (TMAs) refer to a group of rare, life-threatening disorders characterized by the formation of small blood clots within the microvasculature throughout the body. These clots can obstruct blood flow and lead to tissue damage and organ dysfunction. Some common symptoms of the ailment include fatigue, weakness, confusion, fever, pale skin, reduced urine output, headache, visual disturbances, seizures, stroke, blood in the urine, etc. Individuals suffering from this condition may also experience a decrease in the number of platelets, which can result in easy bruising and bleeding tendencies. The diagnosis of TMAs typically involves a combination of clinical evaluation, physical examination, and laboratory tests. Various blood workups, such as coagulation studies, peripheral blood smears, complete blood counts, etc., are also utilized to determine the underlying cause of the disease. Additionally, the healthcare provider may further perform computed tomography (CT) scans to obtain detailed pictures of organs, including the brain and abdomen. In some cases, a kidney biopsy may be necessary to examine the tissue and confirm the diagnosis of TMAs.
The increasing prevalence of inherited genetic mutations that cause gene defects in proteins involved in blood clot regulation, leading to abnormal clot formation, is primarily driving the thrombotic microangiopathies market. In addition to this, the rising cases of overactivation of the immune system, which can damage endothelial cells and result in platelet aggregation, are also creating a positive outlook for the market. Moreover, the widespread adoption of therapeutic plasma exchange (TPE) procedures, since they improve blood flow and microcirculation by reducing the amount of clotting and disrupted blood cells in the body, is further bolstering the market growth. Apart from this, the inflating application of immunosuppressive agents, like rituximab, to dampen the immune response and decrease the production of autoantibodies is acting as another significant growth-inducing factor. Additionally, the emerging popularity of monoclonal antibodies, which are designed to specifically target certain cells or proteins involved in the disease process, thereby minimizing the risk of organ damage, is expected to drive the thrombotic microangiopathies market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the thrombotic microangiopathies market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for thrombotic microangiopathies and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the thrombotic microangiopathies market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the thrombotic microangiopathies market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the thrombotic microangiopathies market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current thrombotic microangiopathies marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the thrombotic microangiopathies market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the thrombotic microangiopathies market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the thrombotic microangiopathies market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of thrombotic microangiopathies across the seven major markets?
What is the number of prevalent cases (2018-2034) of thrombotic microangiopathies by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of thrombotic microangiopathies by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with thrombotic microangiopathies across the seven major markets?
What is the size of the thrombotic microangiopathies patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of thrombotic microangiopathies?
What will be the growth rate of patients across the seven major markets?
Thrombotic Microangiopathies: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for thrombotic microangiopathies drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the thrombotic microangiopathies market?
What are the key regulatory events related to the thrombotic microangiopathies market?
What is the structure of clinical trial landscape by status related to the thrombotic microangiopathies market?
What is the structure of clinical trial landscape by phase related to the thrombotic microangiopathies market?
What is the structure of clinical trial landscape by route of administration related to the thrombotic microangiopathies market?
The thrombotic microangiopathies market has been comprehensively analyzed in IMARC's new report titled "Thrombotic Microangiopathies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Thrombotic microangiopathies (TMAs) refer to a group of rare, life-threatening disorders characterized by the formation of small blood clots within the microvasculature throughout the body. These clots can obstruct blood flow and lead to tissue damage and organ dysfunction. Some common symptoms of the ailment include fatigue, weakness, confusion, fever, pale skin, reduced urine output, headache, visual disturbances, seizures, stroke, blood in the urine, etc. Individuals suffering from this condition may also experience a decrease in the number of platelets, which can result in easy bruising and bleeding tendencies. The diagnosis of TMAs typically involves a combination of clinical evaluation, physical examination, and laboratory tests. Various blood workups, such as coagulation studies, peripheral blood smears, complete blood counts, etc., are also utilized to determine the underlying cause of the disease. Additionally, the healthcare provider may further perform computed tomography (CT) scans to obtain detailed pictures of organs, including the brain and abdomen. In some cases, a kidney biopsy may be necessary to examine the tissue and confirm the diagnosis of TMAs.
The increasing prevalence of inherited genetic mutations that cause gene defects in proteins involved in blood clot regulation, leading to abnormal clot formation, is primarily driving the thrombotic microangiopathies market. In addition to this, the rising cases of overactivation of the immune system, which can damage endothelial cells and result in platelet aggregation, are also creating a positive outlook for the market. Moreover, the widespread adoption of therapeutic plasma exchange (TPE) procedures, since they improve blood flow and microcirculation by reducing the amount of clotting and disrupted blood cells in the body, is further bolstering the market growth. Apart from this, the inflating application of immunosuppressive agents, like rituximab, to dampen the immune response and decrease the production of autoantibodies is acting as another significant growth-inducing factor. Additionally, the emerging popularity of monoclonal antibodies, which are designed to specifically target certain cells or proteins involved in the disease process, thereby minimizing the risk of organ damage, is expected to drive the thrombotic microangiopathies market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the thrombotic microangiopathies market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for thrombotic microangiopathies and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the thrombotic microangiopathies market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the thrombotic microangiopathies market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the thrombotic microangiopathies market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current thrombotic microangiopathies marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the thrombotic microangiopathies market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the thrombotic microangiopathies market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the thrombotic microangiopathies market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of thrombotic microangiopathies across the seven major markets?
What is the number of prevalent cases (2018-2034) of thrombotic microangiopathies by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of thrombotic microangiopathies by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with thrombotic microangiopathies across the seven major markets?
What is the size of the thrombotic microangiopathies patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of thrombotic microangiopathies?
What will be the growth rate of patients across the seven major markets?
Thrombotic Microangiopathies: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for thrombotic microangiopathies drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the thrombotic microangiopathies market?
What are the key regulatory events related to the thrombotic microangiopathies market?
What is the structure of clinical trial landscape by status related to the thrombotic microangiopathies market?
What is the structure of clinical trial landscape by phase related to the thrombotic microangiopathies market?
What is the structure of clinical trial landscape by route of administration related to the thrombotic microangiopathies market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 THROMBOTIC MICROANGIOPATHIES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 THROMBOTIC MICROANGIOPATHIES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 THROMBOTIC MICROANGIOPATHIES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 THROMBOTIC MICROANGIOPATHIES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 THROMBOTIC MICROANGIOPATHIES - UNMET NEEDS
10 THROMBOTIC MICROANGIOPATHIES - KEY ENDPOINTS OF TREATMENT
11 THROMBOTIC MICROANGIOPATHIES - MARKETED PRODUCTS
11.1 List of Thrombotic Microangiopathies Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 THROMBOTIC MICROANGIOPATHIES - PIPELINE DRUGS
12.1 List of Thrombotic Microangiopathies Pipeline Drugs Across the Top 7 Markets
12.1.1 Pegcetacoplan - Apellis Pharmaceuticals/Swedish Orphan Biovitrum
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ravulizumab - Alexion AstraZeneca Rare Disease
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Nomacopan - Akari Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 OMS 721 - Omeros Corporation
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. THROMBOTIC MICROANGIOPATHIES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. THROMBOTIC MICROANGIOPATHIES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 THROMBOTIC MICROANGIOPATHIES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Thrombotic Microangiopathies - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Thrombotic Microangiopathies - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Thrombotic Microangiopathies - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Thrombotic Microangiopathies - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Thrombotic Microangiopathies - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Thrombotic Microangiopathies - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Thrombotic Microangiopathies - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Thrombotic Microangiopathies - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Thrombotic Microangiopathies - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Thrombotic Microangiopathies - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Thrombotic Microangiopathies - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Thrombotic Microangiopathies - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Thrombotic Microangiopathies - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Thrombotic Microangiopathies - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Thrombotic Microangiopathies - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Thrombotic Microangiopathies - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Thrombotic Microangiopathies - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Thrombotic Microangiopathies - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Thrombotic Microangiopathies - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Thrombotic Microangiopathies - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Thrombotic Microangiopathies - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Thrombotic Microangiopathies - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Thrombotic Microangiopathies - Access and Reimbursement Overview
16 THROMBOTIC MICROANGIOPATHIES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 THROMBOTIC MICROANGIOPATHIES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 THROMBOTIC MICROANGIOPATHIES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 THROMBOTIC MICROANGIOPATHIES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 THROMBOTIC MICROANGIOPATHIES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 THROMBOTIC MICROANGIOPATHIES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 THROMBOTIC MICROANGIOPATHIES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 THROMBOTIC MICROANGIOPATHIES - UNMET NEEDS
10 THROMBOTIC MICROANGIOPATHIES - KEY ENDPOINTS OF TREATMENT
11 THROMBOTIC MICROANGIOPATHIES - MARKETED PRODUCTS
11.1 List of Thrombotic Microangiopathies Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 THROMBOTIC MICROANGIOPATHIES - PIPELINE DRUGS
12.1 List of Thrombotic Microangiopathies Pipeline Drugs Across the Top 7 Markets
12.1.1 Pegcetacoplan - Apellis Pharmaceuticals/Swedish Orphan Biovitrum
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ravulizumab - Alexion AstraZeneca Rare Disease
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Nomacopan - Akari Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 OMS 721 - Omeros Corporation
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. THROMBOTIC MICROANGIOPATHIES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. THROMBOTIC MICROANGIOPATHIES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 THROMBOTIC MICROANGIOPATHIES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Thrombotic Microangiopathies - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Thrombotic Microangiopathies - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Thrombotic Microangiopathies - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Thrombotic Microangiopathies - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Thrombotic Microangiopathies - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Thrombotic Microangiopathies - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Thrombotic Microangiopathies - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Thrombotic Microangiopathies - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Thrombotic Microangiopathies - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Thrombotic Microangiopathies - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Thrombotic Microangiopathies - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Thrombotic Microangiopathies - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Thrombotic Microangiopathies - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Thrombotic Microangiopathies - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Thrombotic Microangiopathies - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Thrombotic Microangiopathies - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Thrombotic Microangiopathies - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Thrombotic Microangiopathies - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Thrombotic Microangiopathies - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Thrombotic Microangiopathies - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Thrombotic Microangiopathies - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Thrombotic Microangiopathies - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Thrombotic Microangiopathies - Access and Reimbursement Overview
16 THROMBOTIC MICROANGIOPATHIES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 THROMBOTIC MICROANGIOPATHIES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 THROMBOTIC MICROANGIOPATHIES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
